Replies to post #36551 on Biotech Values

[DewDiligence]

The CEO said the most impressive aspect of the trial vis-à-vis hypoglycemia was that the bedtime oral dose, which was not followed by food, caused no noted hypoglycemia events. The obvious question is how many events were not noted.